Ezabenlimab: all 23 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced CancerNot yet recruitingNCT07851103Phase 1
• A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With EzabenlimabRecruitingNCT07607678Phase 1
• A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)RecruitingNCT05471856Phase 1
• Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive GlioblastomaRecruitingNCT03383978Phase 1
• A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in SurgeryTerminatedNCT05446129Phase 1Results posted
• A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)CompletedNCT04147234Phase 1Results posted
• A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced CancerCompletedNCT03972150Phase 1Results posted
• This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091TerminatedNCT03780725Phase 1Results posted
• A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid TumoursCompletedNCT03468426Phase 1Results posted
• A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have SpreadTerminatedNCT03166631Phase 1Results posted
• A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid TumoursCompletedNCT02952248Phase 1Results posted
• Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaWithdrawnNCT06370871Phase 3
• A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6TerminatedNCT06091930Phase 1
• Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresWithdrawnNCT06084689Phase 2
• A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingNCT05879978Phase 1
• A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT05846516Phase 1
• A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are ToleratedActive, not recruitingNCT05327946Phase 1
• A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerActive, not recruitingNCT04958239Phase 1
• BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)CompletedNCT04839471Phase 2
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell SurfaceCompletedNCT04752215Phase 1
• A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)CompletedNCT04653142Phase 1
• Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal CancerActive, not recruitingNCT04046445Phase 1
• A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid TumoursCompletedNCT03990233Phase 1

← Ezabenlimab overview